

OBJ
LIMITED

DERMAPORTATION
TECHNOLOGY

Wednesday February 09, 2005

FOR IMMEDIATE RELEASE

OBJ REDUCES TRANSDERMAL DRUG DELIVERY TIMES BY 70%

OBJ Limited (OBJ) is pleased to announce that an independent scientific study, by the Western Australia Biomedical Research Institute (WABRI), confirmed that OBJ's electronic drug delivery technology reduced drug delivery times in the study by up to 70%.

In the same study, OBJ's technology mobilised biologically significant levels of the drug prilocaine, compared to passive diffusion where no drug passed through the skin.

In this comprehensive analysis, spanning a three month period, the company's Dermaportation technology reduced the time to onset of action and the time to achieve specific drug levels. In addition, Dermaportation increased the delivery rate of both lignocaine and prilocaine hydrochloride across donated human skin in vitro.

Prilocaine and lignocaine hydrochloride are local anaesthetic drugs that penetrate the skin poorly. OBJ targeted these drugs as a means of demonstrating Dermaportation's ability to increase transdermal delivery rates to create new delivery strategies and expand market opportunities for existing drugs and compounds.

In the WABRI study, Lignocaine concentrations averaged 1.94µg at the 60 minute mark under the influence of Dermaportation, compared with 0.57µg unassisted. The effect was even more pronounced with prilocaine, where concentrations averaged 1.51µg under Dermaportation and zero without. Similar results were seen in time based analysis.

OBJ's drug testing program will continue in preparation for Ethics Committee approval for human trials and will expand to include a range of anti-cancer drugs, human hormones and cosmetic compounds used in anti-aging and anti-scarring applications.

ENDS

OBJ Limited (ACN 056 482 636)

Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007

Phone: +61 9 9443 3011 Fax: +61 9 9443 3866 Email: jedwards@obi.com.au

Background to the Announcement

OBJ Limited is a drug delivery company, developing electronic "drug patch" technologies that allow drugs, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently through-the-skin.

OBJ's technology works by temporarily changing the skin's barrier effect. As this does not involve a change to the target drug or compound, new and effective delivery strategies can be created without the necessity for the drug to undergo costly re-registration. This provides pharmaceutical companies with a market friendly, cost effective and safe route of administration for many existing and newly created drugs and compounds.

The company had previously announced a 600% increase in the rate of delivery of the drug caffeine and a 70% reduction in the through-the-skin delivery times for the anaesthetic drugs lignocaine and prilocaine hydrochloride.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute or WABRI and Universities.

WABRI is a government owned and funded drug development and testing facility operated by Curtin University. The high level of independence and international accreditation means that the results by OBJ can be published and presented at major medical and scientific conferences and forums.

Drug testing Program and Continuous disclosure

OBJ has a continuous drug testing program designed to cover a broad range of existing drugs and compounds used commercially by the cosmetic, oncology, dermatology, endocrinology and general practice sectors.

For more information:

OBJ Limited
Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007
Phone: +61 8 9443 3011
Fax: +61 8 9443 3866
Email: jedwards@obj.com.au